The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

Jaguar Health Completes Effectiveness Trial for Canine Diarrhea Treatment

Key Facts

1Jaguar Health completed the effectiveness study of crofelemer delayed-release tablets for treating chemotherapy-induced diarrhea (CID) in dogs.

2Topline results from the study are expected to be released within one month.

3The drug currently holds conditional FDA approval under the name Canalevia-CA1 for treating CID in dogs.

Create Free Account

Jaguar Health (NASDAQ: JAGX) has announced the completion of its effectiveness study for crofelemer delayed-release tablets, aimed at treating chemotherapy-induced diarrhea (CID) in dogs. The study was designed to provide the clinical data required to transition the drug from its current conditional FDA approval to full regulatory approval. The treatment is presently marketed under the brand name Canalevia-CA1 for veterinary use. Management expects to release the topline results from this trial within the next month. This milestone is a critical step in the company's strategy to monetize its animal health pipeline and expand its commercial footprint. Investors are closely watching the upcoming data as a potential catalyst for the micro-cap biotech stock.